Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World
Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
- Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
- 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
- Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
- The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.